Literature DB >> 3393537

Photophysical studies of tin(IV)-protoporphyrin: potential phototoxicity of a chemotherapeutic agent proposed for the prevention of neonatal jaundice.

E J Land1, A F McDonagh, D J McGarvey, T G Truscott.   

Abstract

The strongly light-absorbing metalloporphyrin tin(IV)-protoporphyrin IX (SnPP) is currently being considered as a chemotherapeutic agent for preventing severe hyperbilirubinemia in newborns, a condition usually treated by phototherapy with visible light. To assess the potential phototoxicity of SnPP we studied the photophysics of the drug in aqueous and nonaqueous solutions using laser flash photolysis and pulse radiolysis. Quantum yields for formation of triplet-state excited SnPP were measured, along with triplet lifetimes and extinction coefficients. In addition, we measured quantum yields for the SnPP-photosensitized formation of singlet oxygen in MeO2H and 2H2O containing cetyltrimethylammonium bromide, using a time-resolved luminescence technique. Quantum yields for formation of triplet SnPP from monomeric ground-state SnPP are high (approximately equal to 0.6-0.8), and triplet lifetimes are long (approximately equal to 0.1-0.2 ms). Efficient quenching of triplet SnPP by molecular oxygen was seen with rate constants greater than 10(9) M-1.s-1. SnPP-photosensitized formation of singlet oxygen in aqueous and nonaqueous solvents was confirmed by the detection of the characteristic luminescence at 1270 nm (phi delta = 0.58 in MeO2H). The photophysical parameters and singlet oxygen-sensitizing efficiency of SnPP are similar to those reported for hematoporphyrin and other metal-free porphyrins known to be phototoxic to humans. These observations suggest that cutaneous photosensitivity arising from singlet-oxygen damage is likely to be an undesirable side-effect of SnPP therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393537      PMCID: PMC281727          DOI: 10.1073/pnas.85.14.5249

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Direct detection of singlet oxygen sensitized by haematoporphyrin and related compounds.

Authors:  J P Keene; D Kessel; E J Land; R W Redmond; T G Truscott
Journal:  Photochem Photobiol       Date:  1986-02       Impact factor: 3.421

Review 2.  Control of heme metabolism with synthetic metalloporphyrins.

Authors:  A Kappas; G S Drummond
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

3.  Ambient light and phototherapy conditions of eight neonatal care units: a summary report.

Authors:  R J Landry; P C Scheidt; R W Hammond
Journal:  Pediatrics       Date:  1985-02       Impact factor: 7.124

Review 4.  'Like a shrivelled blood orange'--bilirubin, jaundice, and phototherapy.

Authors:  A F McDonagh; D A Lightner
Journal:  Pediatrics       Date:  1985-03       Impact factor: 7.124

Review 5.  Pathogenesis and treatment of photocutaneous manifestations of the porphyrias.

Authors:  M B Poh-Fitzpatrick
Journal:  Semin Liver Dis       Date:  1982-05       Impact factor: 6.115

6.  Tin-protoporphyrin: a potent photosensitizer of bilirubin destruction.

Authors:  A F McDonagh; L A Palma
Journal:  Photochem Photobiol       Date:  1985-09       Impact factor: 3.421

7.  Home phototherapy treatment of neonatal jaundice.

Authors:  L D Eggert; R A Pollary; D S Folland; A L Jung
Journal:  Pediatrics       Date:  1985-10       Impact factor: 7.124

8.  Tissue distribution and disposition of tin-protoporphyrin, a potent competitive inhibitor of heme oxygenase.

Authors:  K E Anderson; C S Simionatto; G S Drummond; A Kappas
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

9.  Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans.

Authors:  K E Anderson; C S Simionatto; G S Drummond; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

10.  Biochemical properties of the heme oxygenase inhibitor, Sn-protoporphyrin. Interactions with apomyoglobin and human serum albumin.

Authors:  E Breslow; R Chandra; A Kappas
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

View more
  7 in total

1.  Differential effects of metalloporphyrins on messenger RNA levels of delta-aminolevulinate synthase and heme oxygenase. Studies in cultured chick embryo liver cells.

Authors:  E E Cable; J A Pepe; N C Karamitsios; R W Lambrecht; H L Bonkovsky
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 2.  Metalloporphyrins in the management of neonatal hyperbilirubinemia.

Authors:  David K Stevenson; Ronald J Wong
Journal:  Semin Fetal Neonatal Med       Date:  2009-12-16       Impact factor: 3.926

3.  Theoretical investigations on the hydrolysis pathway of tin verdoheme complexes: elucidation of tin's ring opening inhibition role.

Authors:  Mahdi D Davari; Homayoon Bahrami; Mansour Zahedi; Nasser Safari
Journal:  J Mol Model       Date:  2009-04-17       Impact factor: 1.810

4.  Antimycobacterial effect of IFNG (interferon gamma)-induced autophagy depends on HMOX1 (heme oxygenase 1)-mediated increase in intracellular calcium levels and modulation of PPP3/calcineurin-TFEB (transcription factor EB) axis.

Authors:  Nisha Singh; Pallavi Kansal; Zeeshan Ahmad; Navin Baid; Hariom Kushwaha; Neeraj Khatri; Ashwani Kumar
Journal:  Autophagy       Date:  2018-05-10       Impact factor: 16.016

5.  Metalloporphyrins - an update.

Authors:  Stephanie Schulz; Ronald J Wong; Hendrik J Vreman; David K Stevenson
Journal:  Front Pharmacol       Date:  2012-04-26       Impact factor: 5.810

Review 6.  Heme Oxygenase-1 as a Pharmacological Target for Host-Directed Therapy to Limit Tuberculosis Associated Immunopathology.

Authors:  Krishna C Chinta; Hayden T Pacl; Anupam Agarwal; Adrie J C Steyn
Journal:  Antioxidants (Basel)       Date:  2021-01-26

7.  Photochemotherapeutic strategies against Acanthamoeba keratitis.

Authors:  Ruqaiyyah Siddiqui; Naveed Ahmed Khan
Journal:  AMB Express       Date:  2012-09-05       Impact factor: 3.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.